Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña J L, Navarro E, Martínez-Salmerón J F, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F, Giné J J, Moles J, Gomollón F, Gassull M A
Am J Gastroenterol. 1999 Feb;94(2):427-33. doi: 10.1111/j.1572-0241.1999.872_a.x.
Butyrate enemas may be effective in the treatment of active distal ulcerative colitis. Because colonic fermentation of Plantago ovata seeds (dietary fiber) yields butyrate, the aim of this study was to assess the efficacy and safety of Plantago ovata seeds as compared with mesalamine in maintaining remission in ulcerative colitis.
An open label, parallel-group, multicenter, randomized clinical trial was conducted. A total of 105 patients with ulcerative colitis who were in remission were randomized into groups to receive oral treatment with Plantago ovata seeds (10 g b.i.d.), mesalamine (500 mg t.i.d.), and Plantago ovata seeds plus mesalamine at the same doses. The primary efficacy outcome was maintenance of remission for 12 months.
Of the 105 patients, 102 were included in the final analysis. After 12 months, treatment failure rate was 40% (14 of 35 patients) in the Plantago ovata seed group, 35% (13 of 37) in the mesalamine group, and 30% (nine of 30) in the Plantago ovata plus mesalamine group. Probability of continued remission was similar (Mantel-Cox test, p = 0.67; intent-to-treat analysis). Therapy effects remained unchanged after adjusting for potential confounding variables with a Cox's proportional hazards survival analysis. Three patients were withdrawn because of the development of adverse events consisting of constipation and/or flatulence (Plantago ovata seed group = 1 and Plantago ovata seed plus mesalamine group = 2). A significant increase in fecal butyrate levels (p = 0.018) was observed after Plantago ovata seed administration.
Plantago ovata seeds (dietary fiber) might be as effective as mesalamine to maintain remission in ulcerative colitis.
丁酸盐灌肠剂可能对活动性远端溃疡性结肠炎有效。由于卵叶车前子种子(膳食纤维)的结肠发酵可产生丁酸盐,本研究旨在评估与美沙拉嗪相比,卵叶车前子种子在维持溃疡性结肠炎缓解方面的疗效和安全性。
进行了一项开放标签、平行组、多中心随机临床试验。总共105例处于缓解期的溃疡性结肠炎患者被随机分组,分别接受口服卵叶车前子种子(10克,每日两次)、美沙拉嗪(500毫克,每日三次)以及相同剂量的卵叶车前子种子加美沙拉嗪治疗。主要疗效指标为维持缓解12个月。
105例患者中,102例纳入最终分析。12个月后,卵叶车前子种子组的治疗失败率为40%(35例中的14例),美沙拉嗪组为35%(37例中的13例),卵叶车前子种子加美沙拉嗪组为30%(30例中的9例)。持续缓解的概率相似(Mantel-Cox检验,p = 0.67;意向性治疗分析)。经Cox比例风险生存分析调整潜在混杂变量后,治疗效果保持不变。3例患者因出现便秘和/或肠胃胀气等不良事件而退出研究(卵叶车前子种子组 = 1例,卵叶车前子种子加美沙拉嗪组 = 2例)。服用卵叶车前子种子后,粪便丁酸盐水平显著升高(p = 0.018)。
卵叶车前子种子(膳食纤维)在维持溃疡性结肠炎缓解方面可能与美沙拉嗪同样有效。